Prognose
Analytikernes gennemsnitlige kursmål er 79,74 € (+30,29 %). Medianen er 76,10 € (+24,35 %).
| Køb |
26 |
| Behold |
10 |
| Sælg |
1 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Globus Medical receives CE marking for imaging system Excelsius3D and begins EU/UK commercialization
Globus Medical has received CE marking for commercial distribution of its mobile imaging system Excelsius3D in the European Union and the United Kingdom. Excelsius3D combines 3D cone‑beam CT, 2D fluoroscopy and digital radiography and can be integrated into the robotic navigation system ExcelsiusGPS to enable intraoperative imaging and robot‑assisted navigation. The system was already cleared in the US in 2021 via 510(k); the stock rose slightly in after‑hours trading. » Mere på de.investing.com
Globus Medical acquires digital-health company Higgs Boson Health
Globus Medical announced the acquisition of Higgs Boson Health, a Durham (North Carolina)-based digital-health startup spun out of Duke University. Higgs Boson brings software developers and AI scientists and will be integrated into Globus Medical’s division for digital health technologies. The technology will become part of the “Surgical Intelligence” pillar and be used across the entire patient journey; financial details were not disclosed. » Mere på de.investing.com
Globus Medical exceeds revenue forecast in Q2, raises non‑GAAP earnings target
Globus Medical reported Q2 revenue of $789.6 million and a record non‑GAAP EPS of $1.34; GAAP EPS of $1.10 matched analysts’ estimates. Adjusted EBITDA margin rose to 35.4% and the company generated strong operating cash flow of $412.1 million in the first half of the year. Globus reaffirmed full‑year revenue guidance of $3.18–3.22 billion and raised its non‑GAAP EPS outlook to $4.95–5.05; the stock reacted positively in after‑hours trading. Management cited margin expansion, market‑share gains in spine and trauma, and continued investments in the product pipeline and enabling technologies. » Mere på de.investing.com
Madison Small Cap Fund sells Globus Medical after valuation surpasses its estimate
Madison Small Cap Fund liquidated its multi-year position in Globus Medical, saying the company's post-acquisition success and robotics adoption pushed market value above its intrinsic estimate. The fund cited a market cap near $12 billion and an intrinsic value of $85 per share versus a roughly $90 market price, and said it will reallocate to smaller opportunities. Fund performance and broader market context (value outperformance, AI/geopolitical volatility) were noted in the Q1 2026 letter. » Mere på finance.yahoo.com
Wells Fargo cuts price target on Globus Medical after strong Q1 results
Wells Fargo lowered its price target on Globus Medical to $103 from $104 while maintaining an Overweight rating despite the company reporting fiscal Q1 sales and EPS above consensus. Globus posted worldwide net sales of $759.9 million, up 27.0% (25.5% cc), and base business sales excluding Nevro of $677.2 million, up 13.2% (11.2% cc). Management cited record Q1 earnings, organic revenue growth driven by share gains and procedural volume in core spine, and expansion of the customer base through Enabling Technologies. » Mere på finance.yahoo.com
Virksomhedstal
I det seneste kvartal havde Globus Medical en omsætning på 674,25 mio. € og et nettoresultat på 124,63 mio. €
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 674,25 mio. | 2,89 % |
| Bruttofortjeneste | 468,62 mio. | 13,00 % |
| Nettoresultat | 124,63 mio. | 22,94 % |
| EBITDA | 223,93 mio. | 22,16 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 8,08 mia. € |
Antal aktier | 132,47 mio. |
Højeste/laveste i 52 uger | 92,41 € - 60,72 € |
| Udbytte | Nej |
Beta | 0,96 |
P/E (PE Ratio) | 16,16 |
PEG (PEG Ratio) | 0,49 |
K/I (PB Ratio) | 1,87 |
P/S (PS Ratio) | 2,82 |
Virksomhedsprofil
Globus Medical, Inc. er en medicinsk udstyrsvirksomhed, der udvikler og markedsfører sundhedsløsninger til patienter med muskel- og skeletlidelser i USA og internationalt. Virksomheden tilbyder rygprodukter, såsom traditionelle fusionsimplantater bestående af pedikelskrue- og stangsystemer, pladesystemer, intervertebrale spacere og corpectomy-udstyr til behandling af degenerative tilstande, deformiteter, tumorer og traumer; behandlingsmuligheder inden for bevægelsesbevarende teknologier, som består af dynamisk stabilisering, total diskprotese og interspinøse distraktionsanordninger; interventionelle smertebehandlingsløsninger til behandling af vertebrale kompressionsfrakturer; og regenerative biologiske produkter, der består af allografter og syntetiske alternativer. Virksomheden tilbyder også produkter til behandling af ortopædisk traume, herunder frakturplader, kompressionsskruer, intramedullære negle og eksterne fikseringssystemer; samt løsninger til hofte- og knæled, herunder modulære hoftestammer og acetabulare kopper, samt posterior stabiliserende og cruciatbevarende knæartroplastikimplantater. Derudover distribuerer virksomheden humane celle-, væv- og cellu- og vævsbaserede produkter. Globus Medical, Inc. blev stiftet i 2003 og har hovedkvarter i Audubon, Pennsylvania.
| Navn | Globus Medical |
| CEO | Keith W. Pfeil |
| Hjemsted | Audubon,
pa USA |
| Websted | |
| Sektor | Sundhed |
| Branche | Sundhedsudstyr og -produkter |
| Børsnotering | 03.08.2012 |
| Medarbejdere | 6.000 |
Tickersymboler
| Børs | Symbol |
|---|---|
NYSE | GMED |
Frankfurt | GM0N.F |
Düsseldorf | GM0N.DU |
München | GM0N.MU |